Parmax Pharma [PARMAX] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Parmax Pharma Ltd. wins in 3 metrics, Sun Pharmaceutical Industries Ltd. wins in 14 metrics, with 0 ties. Sun Pharmaceutical Industries Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Parmax Pharma Ltd. | Sun Pharmaceutical Industries Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -5.63 | 36.73 | Sun Pharmaceutical Industries Ltd. |
| Price-to-Book Ratio | -2.43 | 5.15 | Sun Pharmaceutical Industries Ltd. |
| Debt-to-Equity Ratio | -2.38 | 6.68 | Sun Pharmaceutical Industries Ltd. |
| PEG Ratio | -0.06 | 3.59 | Sun Pharmaceutical Industries Ltd. |
| EV/EBITDA | 109.78 | 23.61 | Sun Pharmaceutical Industries Ltd. |
| Profit Margin (TTM) | 15.84% | 19.21% | Sun Pharmaceutical Industries Ltd. |
| Operating Margin (TTM) | -6.82% | 26.17% | Sun Pharmaceutical Industries Ltd. |
| EBITDA Margin (TTM) | N/A | 26.17% | N/A |
| Return on Equity | 105.30% | 15.08% | Parmax Pharma Ltd. |
| Return on Assets (TTM) | -11.17% | 11.87% | Sun Pharmaceutical Industries Ltd. |
| Free Cash Flow (TTM) | $-16.59M | $119.44B | Sun Pharmaceutical Industries Ltd. |
| Dividend Yield | N/A | 0.97% | N/A |
| 1-Year Return | -18.44% | 7.25% | Sun Pharmaceutical Industries Ltd. |
| Price-to-Sales Ratio (TTM) | 0.42 | 7.05 | Parmax Pharma Ltd. |
| Enterprise Value | $197.87M | $3,783.37B | Sun Pharmaceutical Industries Ltd. |
| EV/Revenue Ratio | 0.70 | 6.66 | Parmax Pharma Ltd. |
| Gross Profit Margin (TTM) | 28.35% | 80.96% | Sun Pharmaceutical Industries Ltd. |
| Revenue per Share (TTM) | $75 | $237 | Sun Pharmaceutical Industries Ltd. |
| Earnings per Share (Diluted) | $-13.55 | $45.46 | Sun Pharmaceutical Industries Ltd. |
| Beta (Stock Volatility) | N/A | 0.11 | N/A |
Parmax Pharma Ltd. vs Sun Pharmaceutical Industries Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Parmax Pharma Ltd. | -10.44% | 37.89% | 57.11% | 56.72% | 48.13% | 51.69% |
| Sun Pharmaceutical Industries Ltd. | 0.12% | -1.06% | -2.38% | 1.69% | -2.10% | 3.43% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Parmax Pharma Ltd. | -18.44% | 19.45% | -36.21% | 196.24% | 196.24% | 196.24% |
| Sun Pharmaceutical Industries Ltd. | 7.25% | 79.99% | 166.96% | 144.01% | 669.48% | 2,278.32% |
Performance & Financial Health Analysis: Parmax Pharma Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | PARMAX | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹117.89M | ₹3.88T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 391 | 3,903,142 |
| 90 Day Avg. Volume | 664 | 3,253,866 |
| Last Close | ₹45.73 | ₹1,782.20 |
| 52 Week Range | ₹22.60 - ₹53.38 | ₹1,548.00 - ₹1,916.60 |
| % from 52W High | -14.33% | -7.01% |
| All-Time High | ₹81.90 (Jun 14, 2021) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -44.16% | -9.09% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.71% | 0.14% |
| Quarterly Earnings Growth | -0.31% | 0.16% |
| Financial Health | ||
| Profit Margin (TTM) | 0.16% | 0.19% |
| Operating Margin (TTM) | -0.07% | 0.26% |
| Return on Equity (TTM) | 1.05% | 0.15% |
| Debt to Equity (MRQ) | -2.38 | 6.68 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹-12.94 | ₹324.46 |
| Cash per Share (MRQ) | N/A | ₹115.87 |
| Operating Cash Flow (TTM) | ₹-20,488,477 | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹-20,940,101 | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.97% |
| Last 12-Month Dividend | N/A | ₹16.50 |
Valuation & Enterprise Metrics Analysis: Parmax Pharma Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | PARMAX (Apr 24, 2026) | SUNPHARMA (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -5.63 | 36.73 |
| Forward P/E | N/A | 29.48 |
| PEG Ratio | -0.06 | 3.59 |
| Price to Sales (TTM) | 0.42 | 7.05 |
| Price to Book (MRQ) | -2.43 | 5.15 |
| Market Capitalization | ||
| Market Capitalization | ₹117.89M | ₹3.88T |
| Enterprise Value | ₹197.87M | ₹3.78T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.70 | 6.66 |
| Enterprise to EBITDA | 109.78 | 23.61 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.11 |
| Book Value per Share (MRQ) | ₹-12.94 | ₹324.46 |
Financial Statements Comparison: Parmax Pharma Ltd. vs Sun Pharmaceutical Industries Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | PARMAX (2025) | SUNPHARMA (2025) |
|---|---|---|
| Revenue/Sales | 282.04M | 520.41B |
| Cost of Goods Sold | 237.36M | 121.98B |
| COGS % of Revenue | 84.2% | 23.4% |
| Gross Profit | 44.68M | 398.44B |
| Gross Margin | 15.8% | 76.6% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | -7.77M | 125.81B |
| Operating Margin | -2.8% | 24.2% |
| EBITDA | 1.80M | 167.25B |
| EBITDA Margin | 0.6% | 32.1% |
| Pre-Tax Income | -23.95M | 137.52B |
| Pre-Tax Income % of Revenue | -8.5% | 26.4% |
| Income Tax | -3.01M | 27.72B |
| Income Tax % of Revenue | -1.1% | 5.3% |
| Net Income (Profit) | -20.94M | 109.65B |
| Profit Margin | -7.4% | 21.1% |
Balance Sheet & Liquidity Metrics
| Metric | PARMAX (2025) | SUNPHARMA (2025) |
|---|---|---|
| Cash & Equivalents | 903,279 | 102.69B |
| Total Current Assets | 100.03M | 526.24B |
| Total Current Assets % of Revenue | 35.5% | 101.1% |
| Total Current Liabilities | 130.37M | 181.94B |
| Total Current Liabilities % of Revenue | 46.2% | 35.0% |
| Long-Term Debt | 77.04M | 3.58B |
| Long-Term Debt % of Revenue | 27.3% | 0.7% |
| Total Shareholders Equity | -19.89M | 724.86B |
| Retained Earnings | -64.40M | 578.62B |
| Retained Earnings % of Revenue | -22.8% | 111.2% |
| Property, Plant & Equipment | 17.29M | 100.36B |
Cash Flow Statement Comparison
| Metric | PARMAX (2025) | SUNPHARMA (2025) |
|---|---|---|
| Operating Cash Flow | -20.49M | 110.84B |
| Operating Cash Flow % of Revenue | -7.3% | 21.3% |
| Capital Expenditures | -7.01M | -20.68B |
| Free Cash Flow | -16.59M | 119.44B |
| FCF Margin | -5.9% | 23.0% |
| Debt Repayment | N/A | -43.44B |
| Common Stock Repurchase | N/A | -29.00B |
Short Interest & Institutional Ownership Analysis
| Metric | PARMAX | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 3.74M | 2.40B |
| Float Shares | N/A | 1.07B |
| % Held by Insiders | 64.25% | 55.62% |
| % Held by Institutions | 0.00% | 28.69% |
| % Held by Public | 35.75% | 15.69% |
Dividend Analysis & Yield Comparison: Parmax Pharma Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | PARMAX | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹16.50 |
| Last 12-Month Dividend Yield | N/A | 0.97% |
| 3-Year Avg Annual Dividend | N/A | ₹17.33 |
| 3-Year Avg Dividend Yield | N/A | 0.51% |
| 3-Year Total Dividends | N/A | ₹52.00 |
| Ex-Dividend Date | N/A | Feb 05, 2026 |